Past two years Past Year Past 30 Days
Abstract Views 47 37 0
Full Text Views 0 0 0
PDF Downloads 0 0 0
 
 
 
 
 
 
 
 
 
 
 

Correspondence

Bernard LarouzeInstitut de Médecine et d'Epidémiologie Tropicales Hôpital Claude Bernard 10 Avenue de la Porte d'Aubervilliers, 75019 Paris, France

Search for other papers by Bernard Larouze in
Current site
Google Scholar
PubMed
Close
and
Marie-Christine DazzaInstitut de Médecine et d'Epidémiologie Tropicales Hôpital Claude Bernard 10 Avenue de la Porte d'Aubervilliers, 75019 Paris, France

Search for other papers by Marie-Christine Dazza in
Current site
Google Scholar
PubMed
Close
View More View Less
Restricted access

7 January 1983

To the Editor:

In their interesting article entitled “Evaluation of the antimalarial activity of the phenanthrenemethanol halofantrine (WR 171,669)” (Am. J. Trop. Med. Hyg., 31: 1075–1079, 1982), Cosgriff et al. induced malaria by intravenous injection of parasitized red blood cells obtained from previously infected volunteers. They stated that “All malaria inocula were evaluated for the hepatitis B antigen and were found to be negative.”

However, in experiments such as these, screening for HBsAg might not be sufficient. Indeed, it is well established that the hepatitis B virus (HBV) can be transmitted by blood which is negative for HBsAg. In particular, transfusion studies have shown that blood which is negative for both HBsAg and anti-HBs but positive for anti-HBc might be implicated. Therefore, to reduce this risk further, it might be worth testing the HBsAg-negative inocula, or the HBsAg-negative volunteers from whom the inocula are obtained, for anti-HBc. If anti-HBc is present, anti-HBs should be assayed.

Save